MX2022000603A - Anticuerpo anti-tau y uso del mismo. - Google Patents

Anticuerpo anti-tau y uso del mismo.

Info

Publication number
MX2022000603A
MX2022000603A MX2022000603A MX2022000603A MX2022000603A MX 2022000603 A MX2022000603 A MX 2022000603A MX 2022000603 A MX2022000603 A MX 2022000603A MX 2022000603 A MX2022000603 A MX 2022000603A MX 2022000603 A MX2022000603 A MX 2022000603A
Authority
MX
Mexico
Prior art keywords
tau
present
tau antibody
antibody according
animal model
Prior art date
Application number
MX2022000603A
Other languages
English (en)
Spanish (es)
Inventor
Seung-Yong Yoon
Original Assignee
Adel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adel Inc filed Critical Adel Inc
Publication of MX2022000603A publication Critical patent/MX2022000603A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
MX2022000603A 2019-07-15 2020-07-13 Anticuerpo anti-tau y uso del mismo. MX2022000603A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190085233 2019-07-15
PCT/KR2020/009207 WO2021010712A1 (ko) 2019-07-15 2020-07-13 항-타우 항체 및 이의 용도

Publications (1)

Publication Number Publication Date
MX2022000603A true MX2022000603A (es) 2022-05-20

Family

ID=74088428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000603A MX2022000603A (es) 2019-07-15 2020-07-13 Anticuerpo anti-tau y uso del mismo.

Country Status (16)

Country Link
US (1) US20220204601A1 (enExample)
EP (1) EP4001305B1 (enExample)
JP (1) JP7595061B2 (enExample)
KR (1) KR102196840B1 (enExample)
CN (1) CN114430744B (enExample)
AU (1) AU2020313751A1 (enExample)
BR (1) BR112022000719A2 (enExample)
CA (1) CA3143811A1 (enExample)
CL (1) CL2022000087A1 (enExample)
GB (1) GB2600599B (enExample)
IL (1) IL289813A (enExample)
MX (1) MX2022000603A (enExample)
MY (1) MY207132A (enExample)
PH (1) PH12022550106A1 (enExample)
WO (1) WO2021010712A1 (enExample)
ZA (1) ZA202200724B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別tau之抗體
WO2023039456A1 (en) * 2021-09-09 2023-03-16 The University Of North Carolina At Chapel Hill Monoclonal antibodies targeting acetylated tau and methods of use thereof
EP4405680A1 (en) 2021-09-20 2024-07-31 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
KR20250010000A (ko) * 2022-05-27 2025-01-20 주식회사 진큐어 신규 펩타이드 및 그의 용도
CN115724967A (zh) * 2022-09-21 2023-03-03 天津鸿宇泰生物科技有限公司 一种识别Tau蛋白N端区域的单克隆抗体及其应用
JP2025540336A (ja) * 2022-12-08 2025-12-11 アデル,インク 抗タウ抗体及びペプチドを含む融合体とその用途
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
CN116716352A (zh) * 2023-05-16 2023-09-08 深圳湾实验室 Tau蛋白聚集的细胞模型、其构建方法及应用
CN116693682B (zh) * 2023-06-02 2024-04-19 涌源合生科技(深圳)有限公司 抗Tau蛋白抗体及其制备方法和用途
CN116948025B (zh) * 2023-09-14 2024-04-02 北京凯祥弘康生物科技有限公司 一种抗Tau蛋白的抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130251731A1 (en) 2012-03-22 2013-09-26 The Trustees Of The University Of Pennsylvania Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies
CA2869438C (en) * 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
EP2870176A4 (en) 2012-07-03 2016-09-28 Univ Washington ANTIBODIES DIRECTED AGAINST TAU
TWI734975B (zh) * 2014-06-27 2021-08-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
AR103713A1 (es) * 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
WO2018106889A1 (en) * 2016-12-09 2018-06-14 Cogwellin L.L.C. Diagnosis of alzheimer's disease
WO2018117647A1 (ko) * 2016-12-21 2018-06-28 주식회사 아델 변이된 타우 단백질 단편 및 이의 용도

Also Published As

Publication number Publication date
IL289813A (en) 2022-03-01
CN114430744A (zh) 2022-05-03
MY207132A (en) 2025-01-31
EP4001305A1 (en) 2022-05-25
GB202201160D0 (en) 2022-03-16
GB2600599B (en) 2025-05-21
WO2021010712A1 (ko) 2021-01-21
CA3143811A1 (en) 2021-01-21
JP2022541539A (ja) 2022-09-26
TW202116801A (zh) 2021-05-01
CN114430744B (zh) 2024-06-21
AU2020313751A1 (en) 2022-02-10
US20220204601A1 (en) 2022-06-30
KR102196840B1 (ko) 2020-12-30
BR112022000719A2 (pt) 2022-03-29
EP4001305B1 (en) 2026-07-01
EP4001305A9 (en) 2023-05-24
ZA202200724B (en) 2026-04-29
JP7595061B2 (ja) 2024-12-05
GB2600599A8 (en) 2024-12-25
PH12022550106A1 (en) 2022-11-21
EP4001305A4 (en) 2022-10-12
CL2022000087A1 (es) 2023-03-10
GB2600599A (en) 2022-05-04

Similar Documents

Publication Publication Date Title
GB2600599A8 (en) Anti-tau antibody and use of same
AR132544A2 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
MX2019007480A (es) Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau.
MX2020007527A (es) Tratamiento de enfermedades oftalmologicas.
MX2017006663A (es) Anticuerpos tau humanizados en enfermedad de alzheimer.
CL2018000108A1 (es) Moléculas de anticuerpo que se unen a cd22
MX2018016066A (es) Anticuerpos anti- péptido beta amiloide n3pglu y usos de los mismos.
PE20170768A1 (es) Anticuerpos de union a protofibrillas ab mejorados
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112019006853A2 (pt) composição farmacêutica líquida
MX2017008277A (es) Solucion oftalmica acuosa.
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
MX2019009860A (es) Uso mejorado de neurotoxina botulinica en el tratamiento de sialorrea.
CL2025000935A1 (es) Compuesto de anillo fusionado y producto farmacéutico que lo contiene.
MX389320B (es) Anticuerpos anti-tnfrsf25
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
EA202090945A1 (ru) Анти-msln-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
MX2017015462A (es) Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas.
BR112022011350A2 (pt) Composições e métodos para tratamento e prevenção da influenza
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
MX420767B (es) Proteina de union al factor h modificada
MX2022007919A (es) Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).